Johnson & Johnson Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Joaquin Duato

Chief Executive Officer (CEO)

US$13.1m

Compensación total

Porcentaje del salario del CEO	11.4%
Permanencia del CEO	2yrs
Participación del CEO	0.01%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Joaquin Duato en comparación con los beneficios de Johnson & Johnson?
Fecha	Compensación total	Salario	Ingresos de la empresa
Oct 01 2023	n/a	n/a	US$14b
Jul 02 2023	n/a	n/a	US$14b
Apr 02 2023	n/a	n/a	US$13b
Jan 01 2023	US$13m	US$1m	US$18b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$21b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensación vs. Mercado: Joaquin($USD13.10M) está por encima de la media de empresas de tamaño similar en el mercado AR ($USD5.70M).

Compensación vs. Ingresos: Joaquinha sido coherente con los resultados de la empresa en el último año.

CEO

Joaquin Duato (60 yo)

2yrs

Permanencia

US$13,099,487

Compensación

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Joaquin Duato	CEO & Chairman	2yrs	US$13.10m	0.013% $ 40.9b
Joseph Wolk	Executive VP & CFO	5.5yrs	US$8.82m	0.0022% $ 7.0b
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12yrs	US$8.78m	0.0059% $ 18.8b
Robert Decker	Controller & Chief Accounting Officer	4.1yrs	sin datos	0.00073% $ 2.3b
James Swanson	Executive VP & Chief Information Officer	4.2yrs	sin datos	0.00038% $ 1.2b
Jessica Moore	Vice President of Investor Relations	2.2yrs	sin datos	sin datos
Dirk Brinckman	Chief Compliance Officer	no data	sin datos	sin datos
Elizabeth Forminard	Executive VP & General Counsel	1.3yrs	sin datos	0.00023% $ 738.9m
Peter Fasolo	Executive VP & Chief Human Resources Officer	7.8yrs	US$3.62m	0.0043% $ 13.7b
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	sin datos	sin datos
William Hait	Executive VP	17yrs	sin datos	0.0036% $ 11.6b
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	5.5yrs	sin datos	0.0027% $ 8.8b

4.8yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: DJNJ2El equipo directivo de la empresa se considera experimentado (4.8 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Joaquin Duato	CEO & Chairman	2yrs	US$13.10m	0.013% $ 40.9b
D. Davis	Independent Director	9.6yrs	US$350.00k	sin datos
Anne Mulcahy	Lead Independent Director	15yrs	US$410.00k	0.00033% $ 1.1b
Hubert Joly	Independent Director	4.1yrs	US$340.00k	0.00021% $ 674.7m
Marillyn Hewson	Independent Director	4.8yrs	US$353.59k	0.00012% $ 385.5m
Paula Johnson	Independent Director	less than a year	sin datos	0% $ 0
Mark McClellan	Independent Director	10.3yrs	US$320.00k	sin datos
Mary Beckerle	Independent Director	8.6yrs	US$360.00k	sin datos
Darius Adamczyk	Independent Director	1.9yrs	US$300.16k	0.000040% $ 128.5m
Jennifer Doudna	Independent Director	5.8yrs	US$340.00k	sin datos
Mark Weinberger	Independent Director	4.1yrs	US$340.00k	sin datos
Nadja West	Independent Director	3.1yrs	US$340.00k	sin datos

4.4yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de DJNJ2 se considera experimentada (4.3 años de antigüedad promedio).

Johnson & Johnson Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Johnson & Johnson, Annual General Meeting, Apr 25, 2024

Recent updates

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Johnson & Johnson Announces Planned Presentation of New Non-Clinical Studies

Johnson & Johnson Announces New Analysis of Data from the PionEER AF-PCI Clinical Trial Demonstrating XARELTO®? (rivaroxaban)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson to Showcase its Latest Innovations to Combat Cardiovascular Disease at ACC.24

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Opsynvi as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension

Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Recommends Carvykti®? (Ciltacabtagene Autoleucel) for the Early Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Johnson & Johnson, Annual General Meeting, Apr 25, 2024

Johnson & Johnson to Report Q2, 2024 Results on Jul 17, 2024

Johnson & Johnson Announces the First Data from FRONTIER 2, the Long-Term Extension of the Phase 2b FONTIER 1 Clinical Trial Evaluating JNJ-2113

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Ambrx Biopharma Inc. (NasdaqGS:AMAM) from a group of shareholders.

Johnson & Johnson Announces the U.S. Food and Drug Administration Approves the Supplemental Biologics License Application for TECVAYLI®?

Johnson & Johnson Announces Publication in the New England Journal of Medicine of the Phase 2b FRONTIER 1 Trial Results for JNJ-2113

Johnson & Johnson Reports Positive Topline Results for Nipocalimab from Phase 3 Pivotal Study in Generalized Myasthenia Gravis and Phase 2 Study in Sjögren's Disease

Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seek Approval of DARZALEX FASPRO

Johnson & Johnson Announces New Clinical and Real-World Evidence Data Will Be Featured in 18 Abstracts at This Year's ASCO GU Symposium

Johnson & Johnson Provides Sales Guidance for the Full Year of 2024

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Full Approval for BALVERSA to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Ambrx Biopharma Inc. (NasdaqGS:AMAM) for $1.8 billion.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad